This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Zinc finger CCH-type antiviral 1 (ZC3HAV1; ZAP)	<i>In vitro</i> and mouse studies suggest an oncolytic alphavirus could help treat cancers expressing low levels of ZAP. In cancer cell lines, low levels of ZAP correlated with sensitivity to the oncolytic activity of alphavirus M1. In M1-resistant cancer cell lines, an siRNA targeting ZAP increased sensitivity to the virus compared with a scrambled control siRNA. In mouse models of hepatocellular carcinoma, breast cancer and melanoma, i.v. or intratumoral treatment with M1 increased tumor cell death compared with vehicle. Next steps could include testing alphavirus M1 in additional animal models of cancer.	Patent and licensing status unavailable	Lin, Y. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 6, 2014; doi:10.1073/pnas.1408759111 Contact: Guangmei Yan, Sun Yat-sen University, Guangzhou City, China e-mail: ygm@mail.sysu.edu.cn
SciBX 7(42); doi:10.1038/scibx.2014.1233 Published online Oct. 30, 2014				